

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON BUSINESS DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that, recently, the multi-layer co-extrusion infusion film of Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a wholly-owned subsidiary in the Group, has been selected into the list of Seventh Batch of Single Champion Product Enterprise in Manufacturing Industry (Product) (第七批製造業單項冠軍產品企業(產品)名單) (the “List”) published by the Ministry of Industry and Information Technology of China and the China Federation of Industrial Economics. The List aims to cultivate high-quality manufacturing enterprises, enhance enterprises’ self-innovation capabilities, promote enterprises’ continuous growth in size and strength, promote a higher level of industry chain and supply chain, and promote the build-up of national strength in manufacturing to a new level.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 28 November 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.